中国综合临床
中國綜閤臨床
중국종합림상
Clinical Medicine of China
2015年
12期
1117-1120
,共4页
非小细胞肺癌%多西他赛%重组人血管内皮抑素%化疗
非小細胞肺癌%多西他賽%重組人血管內皮抑素%化療
비소세포폐암%다서타새%중조인혈관내피억소%화료
Non-small-cell lung carcinoma%Docetaxel%rh-endostatin%Chemotherapy
目的 探讨初治后进展的非小细胞肺癌(NSCLC)患者给予多西他赛联合重组人血管内皮抑素治疗的疗效及安全性.方法 选择2010年1月至2013年3月收治的76例一线化疗初治后进展的NSCLC患者,给予多西他赛联合重组人血管内皮抑素(联合组,38例)和单药多西他赛(化疗组,38例)继续治疗,比较两组的疾病进展时间(TTP)、客观缓解率(ORR)、临床受益率(CBR)及不良反应的情况.结果 联合组及化疗组的ORR均为0,CBR分别为63.2％ (24/38)和52.6％(20/38) (P=0.712).联合组及化疗组的TTP分别为(2.6±0.4)、(2.0±0.8)个月(P=0.083).联合组及化疗组经治疗后获疾病稳定患者的TTP分别为(6.2±0.4)、(3.2±0.8)个月,联合组较化疗组要明显延长(P=0.038).联合组及化疗组的不良反应差异均无统计学意义(P均＞0.05).结论 对于初治后进展的NSCLC患者,重组人血管内皮抑素在不增加毒副作用的情况下可延长多西他赛化疗获益患者的TTP.
目的 探討初治後進展的非小細胞肺癌(NSCLC)患者給予多西他賽聯閤重組人血管內皮抑素治療的療效及安全性.方法 選擇2010年1月至2013年3月收治的76例一線化療初治後進展的NSCLC患者,給予多西他賽聯閤重組人血管內皮抑素(聯閤組,38例)和單藥多西他賽(化療組,38例)繼續治療,比較兩組的疾病進展時間(TTP)、客觀緩解率(ORR)、臨床受益率(CBR)及不良反應的情況.結果 聯閤組及化療組的ORR均為0,CBR分彆為63.2％ (24/38)和52.6％(20/38) (P=0.712).聯閤組及化療組的TTP分彆為(2.6±0.4)、(2.0±0.8)箇月(P=0.083).聯閤組及化療組經治療後穫疾病穩定患者的TTP分彆為(6.2±0.4)、(3.2±0.8)箇月,聯閤組較化療組要明顯延長(P=0.038).聯閤組及化療組的不良反應差異均無統計學意義(P均＞0.05).結論 對于初治後進展的NSCLC患者,重組人血管內皮抑素在不增加毒副作用的情況下可延長多西他賽化療穫益患者的TTP.
목적 탐토초치후진전적비소세포폐암(NSCLC)환자급여다서타새연합중조인혈관내피억소치료적료효급안전성.방법 선택2010년1월지2013년3월수치적76례일선화료초치후진전적NSCLC환자,급여다서타새연합중조인혈관내피억소(연합조,38례)화단약다서타새(화료조,38례)계속치료,비교량조적질병진전시간(TTP)、객관완해솔(ORR)、림상수익솔(CBR)급불량반응적정황.결과 연합조급화료조적ORR균위0,CBR분별위63.2％ (24/38)화52.6％(20/38) (P=0.712).연합조급화료조적TTP분별위(2.6±0.4)、(2.0±0.8)개월(P=0.083).연합조급화료조경치료후획질병은정환자적TTP분별위(6.2±0.4)、(3.2±0.8)개월,연합조교화료조요명현연장(P=0.038).연합조급화료조적불량반응차이균무통계학의의(P균＞0.05).결론 대우초치후진전적NSCLC환자,중조인혈관내피억소재불증가독부작용적정황하가연장다서타새화료획익환자적TTP.
Objective To analyze the efficacy and safety of combination of rh-endostatin (Endostar) with docetaxel treatment on patients of non-small cell lung cancer (NSCLC) who presented progressive disease (PD) after first-1ine chemotherapy.Methods From Janury 2010 to March 2013,76 patients with stage Ⅲ B/ Ⅳof NSCLC experienced previous chemotherapy of one-regimen were screened for this trial.Given docetaxel combined with recombinant human endostatin (combined group, 38 cases) and docetaxel (chemotherapy group, 38 cases) to continue treatment.The response, time to progression(TTP) and adverse effects were observed in both groups.Results The objective response rate (ORR) and clinical benefit rate (CBR) were 0 and 63.2％ (24/38) in the combined group, along with 0 and 52.6％ (20/38) in the single docetaxel group, with a nonsignificant difference between the two groups (P =0.712).The median TTPs in the combined and single docetaxel groups were (2.6±0.4) months and (2.0±0.8) months respectively (P =0.083).The median TTPs of the patients with SD after therapeutic cycles in the combined and single docetaxel groups were (6.2±0.4) months and (3.2 ± 0.8) months respectively (P =0.038).The differences between two groups were nonsignificant in adverse, serious adverse and cardiovascular adverse effects(P＞0.05).Conclusion Endostar may prolong TTP in patients with advanced NSCLC benefited from docetaxel treatment without increased toxicities.
